v3.26.1
Note 8 - Segment Reporting - Reconciliation of Net Loss (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Product revenue $ 434   $ 0   $ 835 $ 0
Adjusted cost of product revenue 273   0   643 0
Total other income, net 615   1,107   1,184 2,356
Net loss (24,657) $ (18,581) (19,168) $ (16,795) (43,238) (35,963)
Operating Segments [Member] | Single Reportable Segment [Member]            
Product revenue 434   0   835 0
Adjusted cost of product revenue [1] 245   0   571 0
Cross platform research and engineering [2] 6,078   4,585   11,258 8,535
R&D manufacturing and engineering [3] 3,201   2,941   5,550 4,736
Clinical and regulatory [4] 5,127   2,183   8,387 3,943
General and administrative [5] 4,548   2,742   8,490 5,461
Sales and marketing [6] 1,279   2,362   3,607 4,218
Other segment items [7] 5,228   5,462   7,394 11,426
Total other income, net (615)   (1,107)   (1,184) (2,356)
Net loss $ (24,657)   $ (19,168)   $ (43,238) $ (35,963)
[1] Adjusted cost of product revenue includes material costs, cash compensation costs, fees paid to consultants and outside service providers and organizations, and other expenses relating to manufacturing the Company’s commercial products. It does not include stock-based compensation, depreciation, amortization, IT and facilities costs - see descriptions of Other segment items in footnote 7 and General and administrative in footnote 5 below.
[2] Cross platform research and engineering includes compensation costs, fees paid to consultants and outside service providers and organizations, prototype spending and other expenses relating to the acquisition, design and development of the Company’s clinical stage devices.
[3] R&D manufacturing and engineering includes compensation costs, fees paid to consultants and outside service providers and organizations, and costs associated with the procurement of materials and the manufacturing of the Company’s clinical stage devices.
[4] Clinical and regulatory includes compensation costs, fees paid to consultants and outside service providers and organizations, and costs associated with clinical trials and regulatory approvals required for the development of the Company’s clinical stage devices.
[5] General and administrative includes compensation costs and fees paid to consultants and outside service providers and organizations in support of the administrative functions of the Company, including finance, legal, human resources, IT and facilities.
[6] Sales and marketing includes compensation costs, fees paid to consultants and outside service providers and organizations, costs associated with marketing and sales strategy as well as execution of marketing and sales initiatives for the Company's products.
[7] Other segment items includes stock-based compensation, depreciation and amortization.